Hypercoagulability is a common complication of the systemic inflammation related to
coronavirus disease 2019 creating debate within the critical care community on the …

Introduction A hypercoagulable condition was described in patients with coronavirus
disease 2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing …

ABSTRACT BACKGROUND: The intensity of the thromboprophylaxis needed as a potential
factor for preventing inpatient mortality due to coronavirus disease-19 (COVID-19) remains …

Coagulopathy represents one of the most important determinants of morbidity and mortality
in coronavirus disease-19 (COVID-19). Whether standard thromboprophylaxis is sufficient or …

Background: Thrombotic complications of coronavirus disease 2019 (COVID-19) are a
worrisome aspect of the disease due to their high incidence in critically ill patients and their …

Many COVID-19 patients develop a coagulopathy characterized by thrombocytopenia, minor
prolongation of bleeding times and elevated serum D-dimer and fibrinogen levels, similar to …

Background: The intensity of thromboprophylaxis as potential factor related to in-patient
mortality associated to COVID-19 remains unclear. Methods: This is a retrospective study to …

A pro-thrombotic milieu and a higher risk of thrombotic events were observed in patients with
CoronaVirus disease-19 (COVID-19). Accordingly, recent data suggested a beneficial role of …

Background Heparin administration in COVID-19 patients is recommended by expert
consensus, although evidence about dosage, duration and efficacy are limited. We aim to …

ABSTRACT BACKGROUND: Venous thromboembolism or extensive thrombosis is relatively
common in patients with severe COVID-19 infection and has been associated with …